



Combination Therapy of Antimicrobial

Guest Editor:

Dr. Andrew David Berti

Eugene Applebaum College of
Pharmacy and Health Sciences,
Detroit, MI, USA

Deadline for manuscript
submissions:

closed (16 June 2022)

Message from the Guest Editor

Dear Colleagues,

Effective antimicrobial therapy has permitted entire fields of medicine to develop. However, treatment with a single antibiotic is not always sufficient in terms of antimicrobial potency or prevention of resistance development. This Special Issue seeks manuscript submissions that further our understanding of when combination therapy is appropriate, why combination therapy can be beneficial, and how best to administer antibiotic combinations. We propose topic prompts below, but manuscripts addressing other aspects of combination therapy are welcome:

1. Appropriateness of empiric combination therapy in endovascular *Staphylococcus aureus* infection;
2. Combination therapy as a resistance mitigation strategy;
3. Genetic or physiological mechanisms of antimicrobial synergy;
4. Clinical trial design to assess antimicrobial combinations;
5. Antimicrobial combinations as salvage therapies;
6. Appropriate endpoints to evaluate clinical effectiveness of combination therapy;
7. Appropriate use criteria for initiation of combination therapy;
8. Combination therapy in the context of resistance to one of the agents;
9. Maintaining appropriate combination therapy across transitions of care.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi